Pancreatic Cancer Research

ResearcherWenzhou Medical UniversityActive in the last 2 years

Qiyu Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5463-6459; OpenAlex author ID A5001668691. Sources: OpenAlex.

Their work

Papers
20 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
39
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 4 papers · 2020: 3 papers · 2021: 2 papers · 2022: 5 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 20

  1. Correction: Chloroxine inhibits pancreatic cancer progression through targeted antagonization of the PI3K/AKT/mTOR signaling pathway. Co-author DOI 10.1007/s12094-025-03997-9↗
  2. Chloroxine inhibits pancreatic cancer progression through targeted antagonization of the PI3K/AKT/mTOR signaling pathway. Co-author DOI 10.1007/s12094-023-03328-w↗
  3. Predicting Recurrence in Pancreatic Ductal Adenocarcinoma after Radical Surgery Using an AX-Unet Pancreas Segmentation Model and Dynamic Nomogram. Co-author DOI 10.3390/bioengineering10070828↗
  4. Synthetic oleanane triterpenoid derivative CDDO-Me disrupts cellular bioenergetics to suppress pancreatic ductal adenocarcinoma via targeting SLC1A5. Last author DOI 10.1002/jbt.23192↗
  5. CDK14/β-catenin/TCF4/miR-26b positive feedback regulation modulating pancreatic cancer cell phenotypes in vitro and tumor growth in mice model in vivo. Co-author DOI 10.1002/jgm.3343↗
  6. The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress p… Co-author DOI 10.1038/s41419-022-04573-7↗
  7. Correction: The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability an… Co-author DOI 10.1038/s41419-022-04705-z↗
  8. Inhibition of STAT3Y705 phosphorylation by Stattic suppresses proliferation and induces mitochondrial-dependent apoptosis in pancreatic cancer cells. Co-author DOI 10.1038/s41420-022-00922-9↗
  9. The anti-dysenteric drug fraxetin enhances anti-tumor efficacy of gemcitabine and suppresses pancreatic cancer development by antagonizing STAT3 activation. Co-author DOI 10.18632/aging.203301↗
  10. Pharmacological Inhibition of STAT3 Attenuates Pancreatic Cancer Cell Invasion and Migration By Interacting with TGF-Β/Smad Signaling Co-author DOI 10.21203/rs.3.rs-1055773/v1↗
  11. The Anti-Dysenteric Drug Fraxetin Enhances Anti-Tumor Efficacy of Gemcitabine and Suppresses Pancreatic Cancer Development by Antagonizing STAT3 Activation Co-author DOI 10.21203/rs.3.rs-125318/v1↗
  12. STRAP as a New Therapeutic Target for Poor Prognosis of Pancreatic Ductal Adenocarcinoma Patients Mainly Caused by TP53 Mutation. Last author DOI 10.3389/fonc.2020.594224↗
  13. Isocorydine decrease gemcitabine-resistance by inhibiting epithelial-mesenchymal transition via STAT3 in pancreatic cancer cells. Co-author PMID 32774728↗
  14. LncRNA H19/miR-194/PFTK1 axis modulates the cell proliferation and migration of pancreatic cancer. Co-author DOI 10.1002/jcb.27669↗
  15. The role of lncRNA MSC-AS1/miR-29b-3p axis-mediated CDK14 modulation in pancreatic cancer proliferation and Gemcitabine-induced apoptosis. Co-author DOI 10.1080/15384047.2018.1529121↗
  16. Emodin sensitizes human pancreatic cancer cells to EGFR inhibitor through suppressing Stat3 signaling pathway. Co-author DOI 10.2147/cmar.s221877↗
  17. Restoration of miRNA-148a in pancreatic cancer reduces invasion and metastasis by inhibiting the Wnt/β-catenin signaling pathway via downregulating maternally … Co-author DOI 10.3892/etm.2018.7026↗
  18. Effect of NK4 transduction in bone marrow-derived mesenchymal stem cells on biological characteristics of pancreatic cancer cells. Last author DOI 10.3390/ijms15033729↗
  19. Experimental studies on treatment of pancreatic cancer with double-regulated duplicative adenovirus AdTPHre-hEndo carrying human endostatin gene. Co-author DOI 10.1016/j.pan.2013.05.012↗
  20. [Regulation effect of adipose-derived mesenchymal stem cells on pancreatic cancer cells]. Last author PMID 24330967↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yanyi Xiao · 8 shared papers, 2020–2025 · strength 1.31
  2. Miaomiao Lin · 4 shared papers, 2022–2025 · strength 0.83
  3. Hangcheng Guo · 6 shared papers, 2020–2022 · strength 0.79
  4. Yongheng Bai · 6 shared papers, 2020–2022 · strength 0.79
  5. Hengyue Zhu · 4 shared papers, 2020–2022 · strength 0.53
  6. Yangyang Guo · 4 shared papers, 2020–2022 · strength 0.53
  7. Zhe Chen · 2 shared papers, 2024–2025 · strength 0.52
  8. Huanhuan Wu · 4 shared papers, 2014–2022 · strength 0.49
  9. Yunfeng Shan · 5 shared papers, 2013–2019 · strength 0.41
  10. Yunpeng Sun · 4 shared papers, 2014–2019 · strength 0.36
  11. Jiawei Chen · 2 shared papers, 2021–2022 · strength 0.26
  12. Qinbo Chen · 2 shared papers, 2021–2022 · strength 0.26
  13. Hongbao Yang · 2 shared papers, 2020–2022 · strength 0.26
  14. Percy David Papa Akuetteh · 2 shared papers, 2020–2022 · strength 0.26
  15. Qiandong Zhu · 3 shared papers, 2013–2019 · strength 0.25
  16. Junjie Deng · 2 shared papers, 2020–2021 · strength 0.23
  17. Yunpeng Sun · 1 shared paper, 2022 · strength 0.22
  18. Haixu Ni · 1 shared paper, 2023 · strength 0.18
  19. Xun Li · 1 shared paper, 2023 · strength 0.18
  20. Lei Zhang · 1 shared paper, 2023 · strength 0.18
  21. Fugen Shangguan · 1 shared paper, 2022 · strength 0.15
  22. Shijia Wu · 1 shared paper, 2022 · strength 0.15
  23. Huimin Huang · 1 shared paper, 2022 · strength 0.15
  24. Guihua Jin · 1 shared paper, 2022 · strength 0.15
  25. Linhua Lan · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.